JP2010511598A - グルコース不耐症関連症状を予防若しくは治療するためのヒトｅｐｏ受容体アゴニスト、組成物、方法および用途 - Google Patents

グルコース不耐症関連症状を予防若しくは治療するためのヒトｅｐｏ受容体アゴニスト、組成物、方法および用途 Download PDF

Info

Publication number
JP2010511598A
JP2010511598A JP2009530650A JP2009530650A JP2010511598A JP 2010511598 A JP2010511598 A JP 2010511598A JP 2009530650 A JP2009530650 A JP 2009530650A JP 2009530650 A JP2009530650 A JP 2009530650A JP 2010511598 A JP2010511598 A JP 2010511598A
Authority
JP
Japan
Prior art keywords
epo
receptor agonist
hinge core
epo receptor
core mimetibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009530650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511598A5 (enExample
Inventor
ジエイムズ，イアン・イー
ピチヤ，クリステン
Original Assignee
セントコア・オーソ・バイオテツク・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントコア・オーソ・バイオテツク・インコーポレーテツド filed Critical セントコア・オーソ・バイオテツク・インコーポレーテツド
Publication of JP2010511598A publication Critical patent/JP2010511598A/ja
Publication of JP2010511598A5 publication Critical patent/JP2010511598A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009530650A 2006-09-29 2007-09-28 グルコース不耐症関連症状を予防若しくは治療するためのヒトｅｐｏ受容体アゴニスト、組成物、方法および用途 Pending JP2010511598A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82754106P 2006-09-29 2006-09-29
PCT/US2007/079964 WO2008042800A2 (en) 2006-09-29 2007-09-28 Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions

Publications (2)

Publication Number Publication Date
JP2010511598A true JP2010511598A (ja) 2010-04-15
JP2010511598A5 JP2010511598A5 (enExample) 2010-09-24

Family

ID=39269124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530650A Pending JP2010511598A (ja) 2006-09-29 2007-09-28 グルコース不耐症関連症状を予防若しくは治療するためのヒトｅｐｏ受容体アゴニスト、組成物、方法および用途

Country Status (16)

Country Link
US (1) US20100183592A1 (enExample)
EP (1) EP2109456A2 (enExample)
JP (1) JP2010511598A (enExample)
KR (1) KR20090077935A (enExample)
CN (1) CN101801403A (enExample)
AU (1) AU2007303527A1 (enExample)
BR (1) BRPI0717155A2 (enExample)
CA (1) CA2665037A1 (enExample)
EA (1) EA200970338A3 (enExample)
IL (1) IL197850A0 (enExample)
MX (1) MX2009003441A (enExample)
NZ (1) NZ575824A (enExample)
SG (1) SG175567A1 (enExample)
UA (1) UA98472C2 (enExample)
WO (1) WO2008042800A2 (enExample)
ZA (1) ZA200902916B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015033382A (ja) * 2013-07-11 2015-02-19 Ｊｃｒファーマ株式会社 組換え蛋白質高発現細胞株の選択法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2011377617B2 (en) * 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
CN107998134A (zh) * 2016-11-01 2018-05-08 江苏万邦生化医药股份有限公司 可博美在制备辅助治疗糖尿病足的药物制剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503001A (ja) * 2002-07-26 2006-01-26 イーピーオープラス ゲーエムベーハー ウント コムパニー カーゲー エリスロポエチンの使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
WO2005047297A1 (en) * 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
JP3930870B2 (ja) * 2004-06-02 2007-06-13 シャープ株式会社 電子写真用二成分現像剤
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503001A (ja) * 2002-07-26 2006-01-26 イーピーオープラス ゲーエムベーハー ウント コムパニー カーゲー エリスロポエチンの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012061714; ＥＧＲＩＥ，Ｊ．Ｃ．　ｅｔ　ａｌ: 'Ｄｅｖｅｌｏｐｍｅｎｔ　ａｎｄ　ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ　ｏｆ　ｎｏｖｅｌ　ｅｒｙｔｈｒｏｐｏｉｅｓｉｓ　ｓｔｉｍｕｌａｔｉｎｇ　ｐｒｏｔｅｉｎ　（ＮＥＳＰ）' Ｂｒ　Ｊ　Ｃａｎｃｅｒ Ｖｏｌ．８４　Ｓｕｐｐｌ　１, 2001, ｐ．３-１０ *
JPN6012061716; ＪＯＨＮＳＯＮ，Ｄ．Ｌ．　ｅｔ　ａｌ: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ　ｏｆ　ａ　１３　ａｍｉｎｏ　ａｃｉｄ　ｐｅｐｔｉｄｅ　ｍｉｍｅｔｉｃ　ｏｆ　ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ　ａｎｄ　ｄｅｓｃｒｉｐｔｉｏｎ　ｏｆ　ａｍｉｎｏ　ａｃｉｄｓ　ｃ' Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３７，　Ｎｏ．１１, 1998, ｐ．３６９９-７１０ *
JPN7012004844; 大野敦ら: 'Ｒｅｃｏｍｂｉｎａｎｔ　ｈｕｍａｎ　ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ投与が糖尿病透析患者のＨｂＡ１ｃ値に及ぼす影響' 透析会誌 ２６（９）, 1993, １５３１-４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015033382A (ja) * 2013-07-11 2015-02-19 Ｊｃｒファーマ株式会社 組換え蛋白質高発現細胞株の選択法

Also Published As

Publication number Publication date
MX2009003441A (es) 2009-10-16
ZA200902916B (en) 2010-10-27
WO2008042800A3 (en) 2010-04-01
CN101801403A (zh) 2010-08-11
CA2665037A1 (en) 2008-04-10
EA200970338A3 (ru) 2010-06-30
US20100183592A1 (en) 2010-07-22
AU2007303527A1 (en) 2008-04-10
NZ575824A (en) 2011-11-25
IL197850A0 (en) 2011-08-01
EP2109456A2 (en) 2009-10-21
BRPI0717155A2 (pt) 2013-10-15
SG175567A1 (en) 2011-11-28
KR20090077935A (ko) 2009-07-16
UA98472C2 (ru) 2012-05-25
EA200970338A2 (ru) 2010-04-30
WO2008042800A2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
US7241733B2 (en) Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
KR101201339B1 (ko) 인간 ｅｐｏ 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도
JP5222153B2 (ja) 長い半減期と増強された赤血球形成活性を備えた組換えヒトＥＰＯ−Ｆｃ融合タンパク質
WO2003084477A2 (en) Mammalian cdr mimetibodies, compositions, methods and uses
JP2010514699A (ja) インスリン感受性および脂質プロファイルを改善するための長時間作用型ｇｌｐ−１受容体アゴニストの使用
JP2012525847A (ja) Ｆｇｆ２１変異体およびその使用
JP2007508011A (ja) ヒトヒンジコアミメティボディ、組成物、方法および用途
JP2010511598A (ja) グルコース不耐症関連症状を予防若しくは治療するためのヒトｅｐｏ受容体アゴニスト、組成物、方法および用途
US20120082669A1 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia
US20250257112A1 (en) Parathyroid hormone variants
JP2009526750A (ja) Ｇｌｐ−１アゴニスト、組成物、方法および使用
MXPA06003677A (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100804

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120522

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423